课题基金 / 基金详情

Cellular Mechanisms in Animal Models of Depression

Cellular Mechanisms in Animal Models of Depression
抑郁症动物模型的细胞机制
批准号:
8186065
负责人:
John R. Traynor
金额:
$38.55万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2013-06-30

项目摘要

项目成果

John R. Traynor的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):抑郁症是一种知之甚少的疾病,治疗只对一定比例的人群有效。抗抑郁药物,包括选择性5-羟色胺再摄取抑制剂(SSRIs),是最常用的抗抑郁药物,在抑郁症的动物模型中有效。SSRI通过5-羟色胺受体间接起作用,包括与异源三聚体G蛋白偶联的受体。G蛋白信号转导调节因子(RGS)是一类细胞内蛋白家族,负向调节受体介导的G蛋白信号转导。利用表达RGS不敏感G?I2蛋白的突变小鼠,我们已经确定了5HT1A受体下游的一条途径,该途径介导了抗抑郁和抗焦虑行为。这使得我们认为RGS蛋白对5HT1A受体信号的调节可能在抑郁症中发挥重要作用,从而为抑郁症的治疗提供了一个新的靶点。然而,哺乳动物中有20种RGS蛋白,一种通用的抑制剂可能会产生广泛的影响。在这个提案中,我们试图通过确定引起观察到的表型的受体的位置,抗抑郁药样效应的生化机制,以及涉及的特定RGS蛋白,来了解G?I2偶联的5HT1A受体在抑郁症动物模型中的功能。这项拟议的工作将结合行为、生化和分子生物学方法,在转基因小鼠中敲入RGS不敏感的G?I2蛋白,包括条件敲入动物,避免与代偿性变化相关的问题,并允许G?I2突变的位置特异性表达。这些研究将提供有关抑郁症动物模型中5-羟色胺信号转导的RGS蛋白的知识,并确定抗抑郁药物治疗的新靶点。具体地说,RGS蛋白可能是直接的药物靶点和/或在不增强其有害作用的情况下促进现有SSRI的抗抑郁作用。 公共卫生相关性:抑郁症是一种知之甚少的疾病,影响着大约1000万美国人。此外,抑郁症的治疗对大多数患者都是无效的。我们最近鉴定了一种转基因小鼠模型,该模型表现出抗抑郁药样行为,并对选择性5-羟色胺再摄取抑制剂(SSRI)有很好的反应。这些小鼠携带一种突变,使特定的细胞内信号蛋白(G蛋白)对其内源调节蛋白(RGS蛋白)无反应。这种突变还增加了针对5-羟色胺5HT1a受体的药物的有效性,该受体与几种情绪障碍有关。在这个建议中,我们试图通过行为和生化方法来增加我们对5HT1A受体的理解,并确定参与其调节的特定RGS蛋白(S)。我们的目标是为治疗抑郁症的药物的开发确定新的靶点。
英文摘要
DESCRIPTION (provided by applicant): Depression is an illness that is poorly understood and treatments are only effective in a certain percentage of the population. Antidepressant medications, including selective serotonin reuptake inhibitors (SSRIs), are the most prescribed antidepressant medications and are effective in animal models of depression. SSRI's act indirectly via 5HT receptors including receptors that couple to heterotrimeric G proteins. Regulators of G protein signaling (RGS) are a family of intracellular proteins that negatively modulate receptor-mediated G protein signaling. Using mutant mice expressing an RGS-insensitive G?i2 protein we have identified a pathway downstream of 5HT1A receptors that mediates antidepressant and anti-anxiety behaviors. This led us to consider that RGS protein modulation of 5HT1A receptor signaling may play an important role in depression and so present a novel target for the treatment of depression. However, there are >20 mammalian RGS proteins and a general inhibitor will likely have a broad range of effects. In this proposal we seek to understand the function of G?i2-coupled 5HT1A receptors in animal models of depression by identifying the location of receptors responsible for the observed phenotype, the biochemical mechanism underlying the antidepressant-like effect, and the particular RGS proteins involved. The proposed work will use a combination of behavioral, biochemical and molecular biological approaches in genetically modified mice with knock-in of RGS-insensitive G?i2 protein, including conditional knock-in animals that avoid problems associated with compensatory changes and allow for site-specific expression of the G?i2 mutation. These studies will provide knowledge of RGS proteins in serotonin signaling in animal models of depression and identify novel targets for antidepressant therapy. In particular, RGS proteins may be direct drug targets and/or act to promote the antidepressant actions of currently available SSRI's without enhancing their unwanted effects. PUBLIC HEALTH RELEVANCE: Depression is a poorly understood illness that affects approximately 10 million Americans. Moreover, treatments for depression are ineffective in a majority of patients. We have recently identified a transgenic mouse model that shows antidepressant-like behavior and responds very well to selective serotonin reuptake inhibitors (SSRIs). These mice carry a mutation that renders specific intracellular signaling proteins (G proteins) unresponsive to their endogenous regulators (RGS proteins). This mutation also increases the effectiveness of drugs targeting the serotonin 5HT1A receptor, a receptor that is linked to several mood disorders. In this proposal we seek to increase our understanding of 5HT1A receptors using behavioral and biochemical measures and identify the particular RGS protein(s) involved in their regulation. Our aim is to identify novel targets for the development of agents to treat depressive illness.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel antagonists as fentanyl overdose rescue therapies
Novel antagonists as fentanyl overdose rescue therapies
Regulator of G protein signaling proteins differentially control opiod analgesia: Diversity Supplement
Allosteric Modulation of the Mu-Opioid Receptor
海外基金